Back
Jabil, Inc. 10K Form
Buy
73
JBL
Jabil, Inc.
Last Price:
$235.14
Seasonality Move:
2.02%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-07-09 | 10Q | JBL/Jabil, Inc. Quarterly |
| 2024-04-05 | 10Q | JBL/Jabil, Inc. Quarterly |
| 2024-01-09 | 10Q | JBL/Jabil, Inc. Quarterly |
| 2023-10-20 | 10K | JBL/Jabil, Inc. Annual |
| 2023-06-30 | 10Q | JBL/Jabil, Inc. Quarterly |
| 2023-04-05 | 10Q | JBL/Jabil, Inc. Quarterly |
Receive JBL News And Ratings
See the #1 stock for the next 7 days that we like better than JBL
JBL Financial Statistics
Sales & Book Value
| Annual Sales: | $29.8B |
|---|---|
| Cash Flow: | $228M |
| Price / Cash Flow: | 21.23 |
| Annual Sales: | $14.08 |
| Price / Book: | 16.22 |
Profitability
| EPS (TTM): | 6.43050 |
|---|---|
| Net Income (TTM): | $703M |
| Gross Margin: | $2.6B |
| Return on Equity: | 49.49% |
| Return on Assets: | 3.84% |
Jabil, Inc. Earnings Forecast
Key Jabil, Inc. Financial Ratios
-
The Gross Profit Margin over the past 35 years for JBL is 8.84%.
-
The Selling, General & Administrative Expenses for JBL have been equal to 3.76% of Gross Profit Margin.
-
The Research & Development expenses have been 0.09% of Revenue.
-
The Interest Expense is 22.83% of Operating Income.
-
The Net Earning history of JBL is 2.20% of Total Revenues.
-
Per Share Earnings over the last 35 years have been positive in 18 years.
Jabil, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYSE |
|---|---|
| Industry: | Electronic Equipment, Instruments & Components |
| Sector: | Information Technology |
| Current Symbol: | JBL |
| CUSIP: | 466313 |
| Website: | jabil.com |
Debt
| Debt-to-Equity Ratio: | 2.51 |
|---|---|
| Current Ratio: | 0.99 |
| Quick Ratio: | 0.49 |
Price-to-Earnings
| Trailing P/E Ratio: | 38.79 |
|---|---|
| Forward P/E Ratio: | 16.94 |
JBL Technical Analysis vs Fundamental Analysis
Buy
73
Jabil, Inc. (JBL)
is a Buy
Is Jabil, Inc. a Buy or a Sell?
-
Jabil, Inc. stock is rated a BuyThe current Jabil, Inc. [JBL] share price is $229.78. The Score for JBL is 73, which is 46% above its historic median score of 50, and infers lower risk than normal.